Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: GI, lower digestive

319MO - Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer


12 Sep 2022


Mini Oral session: GI, lower digestive


Molecular Oncology

Tumour Site

Colon and Rectal Cancer


Stacey Cohen


Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048


S.A. Cohen1, P.M. Kasi2, V.N. Aushev3, D.L. Hanna4, G.P. Botta5, S. Sharif6, G. Laliotis3, S. Sharma3, V. Sharma7, A. Alqahtani8, S.R. Chandana9, S. kang10, S. Chakrabarti11, B.G. Somer12, A. Kasi13, F. Dayyani14, M. Malla15, A. Jurdi3, A. Aleshin3, S. Kopetz16

Author affiliations

  • 1 Medical Oncology, University of Washington and Fred Hutchinson Cancer Center, WA 98109 - Seattle/US
  • 2 Oncology/hematology Department, Weill Cornell Medicine, Englander Institute of Precision Medicine, New York Presbyterian Hospital, 10021 - New York City/US
  • 3 Oncology, Natera, Inc., 78753 - Austin/US
  • 4 Medical Oncology, USC - University of Southern California - Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 5 Medicine, Division Of Hematology/oncology, UCSD Moores Cancer Center, 92093 - La Jolla/US
  • 6 Medical Oncology, University of Iowa Holden Comprehensive Cancer Center, 52242 - Iowa City/US
  • 7 Medical Oncology, James Graham Brown Cancer Center, 40202 - Louisville/US
  • 8 Medical Oncology, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center - Georgetown University Medical Center, 20007 - Washington DC/US
  • 9 Oncology/hematology Department, Cancer and Hematology Centers of Western Michigan, 49546 - Grand Rapids/US
  • 10 Oncology/hematology Department, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 11 Medical Oncology, Medical College of Wisconsin, 53226 - Milwaukee/US
  • 12 Medical Oncology, West Cancer Center, 38104 - Germantown/US
  • 13 Medical Oncology, KUMC - University of Kansas Medical Center, 66160 - Kansas City/US
  • 14 Medicine Department, University of California Irvine Chao Family Comprehensive Cancer Center, 92868 - Orange/US
  • 15 Hematology-oncology, West Virginia University Cancer Institute, 26506 - Morgantown/US
  • 16 Gi Medical Oncology Department, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US


Login to access the resources on OncologyPRO.

Abstract 319MO


Despite earlier screening and advancements in diagnostic and treatment modalities, nearly 25-40% of patients with resected stage I-III colorectal cancer (CRC) recur. A novel approach to post-surgical risk stratification for molecular residual disease (MRD) detection and treatment monitoring is needed to improve patient outcomes.


In this retrospective analysis of a U.S-based multi-institutional study, data from commercial circulating tumor DNA (ctDNA) testing of approximately 12,000 stage I-III CRC patients were analyzed. Complete clinical data was available for 400 patients with 2,140 plasma samples collected between 06/2019-04/2022. A personalized, tumor-informed multiplex PCR-based next-generation sequencing assay (Signatera™) was used to quantify ctDNA prior to surgery, postoperatively (MRD-window; within 8 weeks of surgery, prior to therapy) and during surveillance.


Of 12,000 patients, ctDNA during the MRD-window was tested in 5,684 patients with an overall ctDNA positivity rate of 22.1% (1,259/5,684) and higher positivity rates among stage III (29.5%, 805/2732) patients. In patients with available clinical data (N=400), ctDNA during the MRD-window was tested in 124 patients with a positivity rate of 21.8% (27/124). During the follow-up period (median 626 days; range: 0-3517 days), 63.0% (17/27) of MRD-positive patients relapsed compared to 9.3% (9/97) of MRD-negative patients. Notably, of these 9 relapsed MRD-negative patients, 7 became ctDNA-positive on serial testing beyond 8 weeks. ctDNA positivity during the MRD-window, anytime post-surgery and during surveillance was significantly associated with shorter recurrence-free survival (HR=12.2, 95%CI: 5.3−27.8, p<0.0001), (HR=16.7, 95%CI: 7.4−37.4, p<0.0001), and (HR=25.4, 95%CI: 12.6−51.3, p<0.0001), respectively.


In this study utilizing real-world data from patients with early-stage CRC, postsurgical ctDNA detection at any time point was prognostic of relapse. Postsurgical ctDNA testing in early-stage CRC patients may enable personalized surveillance, intervention, and/or trial options, ultimately improving patient outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Natera, Inc.


Has not received any funding.


S.A. Cohen: Financial Interests, Personal, Advisory Board: Boston Biomedical, Polaris; Financial Interests, Personal, Speaker’s Bureau: Natera, Inc. P.M. Kasi: Financial Interests, Personal, Advisory Board, Consultancy/Advisory Board: Foundation Medicine, Natera Oncology, AstraZeneca, Merck MSD, Tempus, Bayer, Lilly, Delicath Systems, QED Therapeutics, Servier, Taiho Oncology, Exact Sciences, Eisai; Financial Interests, Institutional, Advisory Board, Consultancy/Advisory Board: Taiho, Ipsen; Financial Interests, Institutional, Funding, Investigator initiated trial cooperative group PI trial support and funding.: Tersera; Financial Interests, Institutional, Funding, Investigator initiated trial trial support and funding.: Boston Scientific. V.N. Aushev: Financial Interests, Personal and Institutional, Stocks/Shares: Natera, Inc. D.L. Hanna: Financial Interests, Personal, Advisory Board: Natera, Inc. G.P. Botta: Financial Interests, Personal, Advisory Board: Natera, Inc.; Financial Interests, Personal, Invited Speaker: Natera; Financial Interests, Personal, Funding: Carsgen. G. Laliotis: Financial Interests, Personal and Institutional, Stocks/Shares: Natera, Inc. S. Sharma: Financial Interests, Personal and Institutional, Stocks/Shares: Natera, Inc. S.R. Chandana: Financial Interests, Personal, Invited Speaker: Natera, Inc. S. Chakrabarti: Financial Interests, Personal, Invited Speaker, Speaker bureau: Natera Inc; Financial Interests, Personal, Other, Advisory role: QED THerapeutics. A. Kasi: Financial Interests, Personal, Other, Honoraria: OncLive; Financial Interests, Institutional, Funding: Tesaro, Halozyme, Astellas Pharma, Rafael Pharmaceuticals, Geistlich Pharma, Cardiff Oncology, FibroGen, Bavarian Nordic, Novocure; Financial Interests, Personal, Other, travel, accomodations: Halozyme, Rafael Pharmaceuticals. F. Dayyani: Financial Interests, Personal, Advisory Board: AstraZeneca, Natera, Inc., Exelixis, Genetech; Financial Interests, Personal, Other: Deciphera, Eisai, Exelixis, Ipsen, Natera, Inc., Sirtex; Financial Interests, Personal, Other, Natera, Inc.: Servier; Financial Interests, Personal, Research Grant: AstraZeneca, BMS, Taiho, Exelixis, Merck, Natera, Inc., Ipsen; Financial Interests, Personal, Research Grant, Natera, Inc.: Trishula. M. Malla: Financial Interests, Personal and Institutional, Research Grant, (Grant # 5U54GM104942-05): National Institute of General Medical Sciences-NIH; Financial Interests, Personal, Advisory Role, Natera, Inc.: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Natera, Inc.. A. Jurdi: Financial Interests, Personal and Institutional, Stocks/Shares: Natera, Inc.. A. Aleshin: Financial Interests, Personal and Institutional, Stocks/Shares: Natera, Inc.. S. Kopetz: Financial Interests, Personal, Advisory Board: Roche, EMD Serono, Merck, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca, Bayer, Pierre Fabre, Redx Pharma, Ipsen, Daiichi, Natera, HalioDx, Jacobio, Pfizer, Repare Therapeutics, GlaxoSmithKline, Jazz, Xilis, Abbvie, Gilead, Mirati, Flame, Servier, Carina, Bicara, Endeavor BioMedicines, Numab Pharma, Janssen; Financial Interests, Personal, Other, Research: Inivata; Financial Interests, Personal, Stocks/Shares: Lutris, Iylon, Navire, Xilis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.